[ad_1]
the vaccine against COVID-19–19 developed by Pfizer Y BioΝTech is “90% effective”, the two announced today laboratories after the first scan in the middle of Phase 3, as well as the last evaluation will be done before requesting License.
The two companies behind the formulation described their findings as “Beautiful day for science and humanity “.
The vaccine was tested on 43,500 people in six countries without worrying about security of those who received it, broadcasts the BBC.
The two companies, in fact, plan to present request for urgent approval of the use of the vaccine by end of the month.
The battle to find an effective one vaccine against coronavirus continues at a rapid pace around the world as it is considered the safest path so that countries get out of the restrictions of several months in the daily lives of their citizens.
Right now about 12 vaccines They are in the final stages of testing, however this is the first to show results.
This vaccine is given to two doses with a difference of three weeks. Tests conducted in the US, Germany, Brazil, Argentina, South Africa, and Turkey show that 90% protection was achieved seven days after the second dose.
Pfizer believes it will be able to supply up to 50 million installments until the end of this year and around 1.3 billion until its end 2021.
However, there are several challenges, as the vaccine must be stored at temperatures below:80 degree centigradeWhile there are doubts about how long it will provide immunity.
His head Pfizer, Dr. Albert Burla said: “We are one step closer to bringing people around the world this crucial discovery that will help end this global health crisis.”
In a similar climate, Professor Ugur Sahin, one of its founders BioNTech, described the results as a “milestone.”
Pfizer and BioNTech announced in September that they had completed their exploratory discussions with European Comission for the proposed supply 200 million doses of the mRNA BNT162 vaccine candidate for research against SARS-CoV-2 in the Member States of the European Union, with the possibility of supplying 100 million additional doses.
If taken Excuse me by regulatory authorities, vaccine deliveries will begin at the end of 2020.
